2 recruiting. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Recruiting 2 |
Follow Azacitidine Injection: new trials by email Literature Review of Azacitidine Injection trials Research Report on Azacitidine Injection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4). Lisaftoclax (APG-2575), Azacitidine Injection, Placebo - Higher-risk Myelodysplastic Syndrome | Phase 3 | Recruiting | Ascentage Pharma Group Inc. | 490 | 2025-01-22 | 2026-10-13 |
| A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia APG-2575(Lisaftoclax ), Placebo, Azacitidine Injection - Acute Myeloid Leukemia | Phase 3 | Recruiting | Ascentage Pharma Group Inc. | 486 | 2024-06-11 | 2025-11-25 |
Ascentage Pharma Group Inc. (2)
China (2) · Australia (1) · Belgium (1) · Bulgaria (1) · Canada (1) · Czechia (1) · Finland (1) · France (1) · Germany (1) · Greece (1) · Hungary (1) · Italy (1) · Norway (1) · Poland (1) · Russia (1)
Guillermo Garcia-Manero, M.D. (1) · Jianxiang Wang, M.D. (1) · Jie Jin, M.D. (1) · Xiaojun Huang, M.D., Ph.D. (1)